DBV Technologies releases Q2 and H1 2026 financial results and a business update on its immunotherapy programs
Executive summary: DBV Technologies issued a press release detailing its second‑quarter and half‑year 2026 financial results and gave a business update on its immunotherapy pipeline. The results offer concrete data on the company’s current financial performance and outlook, which informs investors about cash runway and potential near‑term catalysts.
Who is involved: DBV Technologies (Châtillon, France), its executive management team, and shareholders/analysts following the stock.
Likely next: The company may hold an earnings call to discuss the results, and investors will watch for upcoming clinical trial readouts or regulatory feedback on its Viaskin® products.
DBV Technologies published its second‑quarter and half‑year 2026 financial results, providing the market with updated figures on revenue, expenses and cash position. The release also includes a brief business update on the progress of its epicutaneous immunotherapy platform, particularly the Viaskin® peanut and milk programs. Investors can use this information to gauge the company’s short‑term financial health and the near‑term milestones of its pipeline.
Timeline
- — DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update (GlobeNewswire)
- — DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 (GlobeNewswire)